Considering the potential impact of driver gene alterations and PD-L1 expression level on the efficacy of ICIs treatment in advanced NSCLC, we therefore conducted the subgroup analysis based on the driver gene status and PD-L1 expression in BrM group. The gene discussed is CD274; the disease is non-small cell lung carcinoma.